CD4 and Ebola hemorrhagic fever: The prolonged two-phase study to monitor the effectiveness of Ebola vaccine for the respirational and sublingual (SL) adenovirus in non-human primates revealed durable protection from a single dose in monkeys with diverse Ebola GP-specific CD4+ T cells generation, and was an unstable approach [54].